Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US

Journal of Cystic Fibrosis(2025)10.1016/j.jcf.2025.06.005Source: DataRank Database

Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US is a research paper published in Journal of Cystic Fibrosis (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.00)OA: greenTopics (57)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Miranda C. Bradford ORCID,Sonya L. Heltshe ORCID,T. Milinic ORCID,Oliver J. McElvaney ORCID,Erika D. Lease ORCID

Live enrichment

PubMed:40603159 OpenAlex:https://openalex.org/W4411921870

NHLBI NIH HHS

Grant: T32 HL125195

NIDDK NIH HHS

Grant: P30 DK089507

NINR NIH HHS

Grant: R01 NR020470

NHLBI NIH HHS

Grant: R33 HL158811

National Institute of Nursing Research

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases

FWCI

0.00

Citation Percentile

0.2%

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40603159/

publisherhttps://api.elsevier.com/content/article/PII:S156919932501519X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S156919932501519X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2025.06.005

Fields of Study

Cystic Fibrosis Research AdvancesTransplantation: Methods and OutcomesImmunodeficiency and Autoimmune DisordersHumansCystic FibrosisLung TransplantationMaleFemaleCross-Sectional StudiesRetrospective StudiesAminophenolsQuinolonesUnited StatesAdultBenzodioxolesDrug CombinationsChloride Channel AgonistsPractice Patterns, Physicians'IndolesPyrazolesPyridinesPyrrolidinesDrug PrescriptionsRegistries

MeSH Terms

AdultAminophenolsCross-Sectional StudiesCystic FibrosisDrug CombinationsFemaleHumansIndolesMalePractice Patterns, Physicians'Drug PrescriptionsPyrazolesPyridinesPyrrolidinesRegistriesRetrospective StudiesUnited StatesQuinolonesLung TransplantationBenzodioxolesChloride Channel Agonists

Keywords

MedicineIvacaftorCystic fibrosisMedical prescriptionInternal medicineLogistic regressionPharmacologyCystic fibrosis transmembrane conductance regulatorLung transplantationCftr ModulatorTezacaftorElexacaftor

Sustainable Development Goals

SDG 0: Zero hunger